FDA imposes heart attack, stroke warnings on testosterones
This article was originally published in Scrip
Executive Summary
The FDA on 3 March said it was imposing new warnings on the labeling of testosterone replacement therapies (TRTs), like AbbVie's $1bn drug AndroGel, about an increased risk of heart attack and stroke.